Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_assertion description "[Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_assertion evidence source_evidence_literature NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_assertion SIO_000772 20660056 NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_assertion wasDerivedFrom befree-2016 NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_assertion wasGeneratedBy ECO_0000203 NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.
- befree-2016 importedOn "2016-02-19" NP828309.RAdakdRe7JpUo4Hc01QLndaSvJ3GRKj5cKOKt6VF1hYn0130_provenance.